Science Explorer Back to mapMap
Discussion
Topic · Molecular Biology

Melanoma and MAPK Pathways

Melanoma and MAPK Pathways is a research topic within Molecular Biology. Science Explorer counts 20k research works in it since 1950. 10.3% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the mammalian MAP kinase signaling pathways, particularly their role in cancer, with a specific emphasis on melanoma. It covers the genetic mutations, targeted therapies, resistance mechanisms, and the impact of MAP kinase pathways on cell proliferation and immune response.

  • MAP Kinase
  • BRAF gene
  • Melanoma
  • Signal Transduction
  • ERK pathway
  • Cancer Therapy
  • MEK Inhibition
  • Cell Proliferation
  • Oncogenic Mutations
  • Immune Response
Research works
20k
fractional, since 1950
In the world top 10%
2k
per year above
Top-10% rate
10.3%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+6%
the tick is no change
Largest producer
United States
39% of the 10 largest, 2022-now
Melanoma and MAPK Pathways

Which countries lead Melanoma and MAPK Pathways research?

By volume, the United States and China publish the most (1.3k and 758 works in 2022-now).

By volume, 2022-now

  1. 1 United States 1.3k works
  2. 2 China 758 works
  3. 3 Germany 207 works
  4. 4 Italy 199 works
  5. 5 Japan 169 works
  6. 6 France 150 works
  7. 7 India 149 works
  8. 8 United Kingdom 139 works
  9. 9 Spain 125 works
  10. 10 Australia 122 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 39.3%China: 22.8%Germany: 6.2%Italy: 6.0%6 others listed: 25.7%39%largest
United States1,308 · 39.3%China758 · 22.8%Germany207 · 6.2%Italy199 · 6.0%6 others listed853 · 25.7%

Shares of the rows listed above, not of the whole node.

Which institutions lead Melanoma and MAPK Pathways research?

By volume in 2022-now, Harvard University publishes the most Melanoma and MAPK Pathways research, followed by The University of Texas MD Anderson Cancer Center and The University of Sydney.

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 66 works
  2. 2 The University of Texas MD Anderson Cancer CenterUnited States 44 works
  3. 3 The University of SydneyAustralia 30 works
  4. 4 Mayo ClinicUnited States 27 works
  5. 5 University of North Carolina at Chapel HillUnited States 26 works
  6. 6 National Institutes of HealthUnited States 26 works
  7. 7 Peking UniversityChina 23 works
  8. 8 Moffitt Cancer CenterUnited States 22 works
  9. 9 Sichuan UniversityChina 22 works
  10. 10 Memorial Sloan Kettering Cancer CenterUnited States 22 works

Who are the leading researchers in Melanoma and MAPK Pathways?

The most-cited researchers publishing on Melanoma and MAPK Pathways include Ahmedin Jemal, Freddie Bray and Eric S. Lander.

  1. 1 Ahmedin Jemal United States 761k citations
  2. 2 Freddie Bray France 550k citations
  3. 3 Eric S. Lander United States 524k citations
  4. 4 Mark J. Daly United States 403k citations
  5. 5 Stacey L. Gabriel United States 402k citations
  6. 6 Julian P. T. Higgins United Kingdom 390k citations
  7. 7 Gad A. Getz United States 364k citations
  8. 8 Elaine R. Mardis United States 346k citations
  9. 9 Hermann Brenner Germany 343k citations
  10. 10 Shizuo Akira Japan 342k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Melanoma and MAPK Pathways?

The most cited paper in Melanoma and MAPK Pathways is "Mutations of the BRAF gene in human cancer" (Helen Ruth Davies et al., 2002), with 10,791 citations. Next come "The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity" (8,623) and "Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma" (8,266).

Most cited papers
#PaperReleasedCitations
1 Mutations of the BRAF gene in human cancer Helen Ruth Davies et al. · Nature Jun 2002 10,791
2 The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Jordi Barretina et al. · Nature Open access 27 Mar 2012 8,623
3 Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma James Larkin et al. · New England Journal of Medicine Open access 31 May 2015 8,266
4 Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation Paul B. Chapman et al. · New England Journal of Medicine Open access 5 Jun 2011 7,801
5 Pembrolizumab versus Ipilimumab in Advanced Melanoma Caroline Robert et al. · New England Journal of Medicine Open access 19 Apr 2015 5,968
All 99 most cited papers, with filters and sorting

Where is Melanoma and MAPK Pathways research done?

The largest centres of Melanoma and MAPK Pathways research in 2022-now are New York (United States), Beijing (China), Shanghai (China) and Houston (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Tampa, Heidelberg and Houston.

Largest cities, 2022-now

  1. 1 New YorkUnited States 87 works
  2. 2 BeijingChina 84 works
  3. 3 ShanghaiChina 75 works
  4. 4 HoustonUnited States 62 works
  5. 5 BostonUnited States 55 works
  6. 6 ParisFrance 50 works
  7. 7 GuangzhouChina 49 works
  8. 8 PhiladelphiaUnited States 46 works
  9. 9 SydneyAustralia 44 works
  10. 10 SeoulSouth Korea 44 works

Where it is the local speciality

  1. TampaUS · 29.9 works10×
  2. HeidelbergDE · 27.2 works6.3×
  3. HoustonUS · 61.8 works5.9×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Melanoma and MAPK Pathways than the world average.

See Melanoma and MAPK Pathways on the map

Where is the best place to study Melanoma and MAPK Pathways?

Among universities, judged by research, Harvard University, The University of Sydney and Cornell University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%mean 17.24%fractional works in this field (log) →share of work in the world top 10% →The University of Sy…Harvard UniversityCornell UniversityUniversity of Califo…
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 87.318.2%5.5×66 -3.6%
2The University of SydneyAustralia 70.619.7%6.4×30 +1.8%
3Cornell UniversityUnited States 63.316.1%3.2×16 +20.0%
4University of California, San FranciscoUnited States 60.711.5%7.8×21 +2.1%
5University of UtahUnited States 58.816.3%7.0×18 +20.4%
6Johns Hopkins UniversityUnited States 58.319.8%2.7×16 +20.3%
7Sichuan UniversityChina 57.120.2%2.6×22 +37.2%
8Peking UniversityChina 49.214.4%3.0×23 +1.6%
9Vanderbilt UniversityUnited States 48.821.8%4.2×11 -27.3%
10Stanford UniversityUnited States 47.714.4%2.4×13 +10.0%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Melanoma and MAPK Pathways, country by country

Is Melanoma and MAPK Pathways research growing?

Output in 2022-2025 was 6% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Melanoma and MAPK Pathways.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Melanoma and MAPK Pathways as a percentage of every work published that year, 0.016% in 2024.

still counting0.010%0.020%0.030%Melanoma and MAPK Pathways0.019% in 202519801990200020102020

Fractional works of Melanoma and MAPK Pathways over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Melanoma and MAPK Pathways10.4% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Melanoma and MAPK Pathways. Posts are plain text and can be reported.